Literature DB >> 9817708

Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease.

D E O'Donnell1, M Lam, K A Webb.   

Abstract

Changes in lung hyperinflation, dyspnea, and exercise endurance are important outcomes in assessing therapeutic responses in chronic obstructive pulmonary disease (COPD). Therefore, we studied the reproducibility of Borg dyspnea ratings, inspiratory capacity (IC; to monitor lung hyperinflation), and endurance time during constant-load symptom-limited cycle exercise in 29 patients with COPD (FEV1 = 40 +/- 2% predicted; mean +/- SEM). Responsiveness was also studied by determining the acute effects of nebulized 500 micrograms ipratropium bromide (IB) or saline placebo (P) on these measurements. During each of four visits conducted over an 8-wk period, spirometry and exercise testing were performed before and 1 h after receiving IB or P (randomized, double-blinded). Highly reproducible measurements included: endurance time (intraclass correlation R = 0.77, p < 0.0001); Borg ratings and IC at rest, at a standardized exercise time (STD), and at peak exercise (R > 0.6, p < 0.0001); and slopes of Borg ratings over time, oxygen consumption (V O2), and ventilation (R > 0.6, p < 0.0001). Responsiveness was confirmed by finding a significant drug effect for: change (Delta) in endurance time (p = 0.0001); DeltaBorgSTD and DeltaBorg-time slopes (p < 0.05); and DeltaIC at rest, at STD, and at peak exercise (p = 0.0001). With all completed visits, DeltaBorgSTD correlated better with DeltaICSTD than any other resting or exercise parameter (n = 115, r = -0.35, p < 0.001). We concluded that Borg dyspnea ratings, and measurements of IC and endurance time during submaximal cycle exercise testing are highly reproducible and responsive to change in severe COPD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9817708     DOI: 10.1164/ajrccm.158.5.9804004

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  82 in total

Review 1.  Alternatives to lung transplantation: lung volume reduction for COPD.

Authors:  Gerard J Criner
Journal:  Clin Chest Med       Date:  2011-06       Impact factor: 2.878

Review 2.  Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004.

Authors:  M Decramer; R Gosselink; M Rutten-Van Mölken; J Buffels; O Van Schayck; P-A Gevenois; R Pellegrino; E Derom; W De Backer
Journal:  Thorax       Date:  2005-04       Impact factor: 9.139

3.  The confounding effects of thoracic gas compression on measurement of acute bronchodilator response.

Authors:  Amir Sharafkhaneh; Tony G Babb; Todd M Officer; Nicholas A Hanania; Hossein Sharafkhaneh; Aladin M Boriek
Journal:  Am J Respir Crit Care Med       Date:  2006-11-16       Impact factor: 21.405

Review 4.  Optimum bronchodilator combinations in chronic obstructive pulmonary disease: what is the current evidence?

Authors:  Matthew C Miles; James F Donohue; Jill A Ohar
Journal:  Drugs       Date:  2012-02-12       Impact factor: 9.546

5.  Effect of Yoga Breathing (Pranayama) on Exercise Tolerance in Patients with Chronic Obstructive Pulmonary Disease: A Randomized, Controlled Trial.

Authors:  David A Kaminsky; Kalpalatha K Guntupalli; Joan Lippmann; Stephanie M Burns; Melissa A Brock; Joan Skelly; Michael DeSarno; Heidi Pecott-Grimm; Ali Mohsin; Catherine LaRock-McMahon; Penney Warren; Martha C Whitney; Nicola A Hanania
Journal:  J Altern Complement Med       Date:  2017-07-17       Impact factor: 2.579

6.  Patterns of dynamic hyperinflation during exercise and recovery in patients with severe chronic obstructive pulmonary disease.

Authors:  I Vogiatzis; O Georgiadou; S Golemati; A Aliverti; E Kosmas; E Kastanakis; N Geladas; A Koutsoukou; S Nanas; S Zakynthinos; C Roussos
Journal:  Thorax       Date:  2005-06-17       Impact factor: 9.139

Review 7.  Opioids for chronic refractory breathlessness: right patient, right route?

Authors:  David C Currow; Magnus Ekstrom; Amy P Abernethy
Journal:  Drugs       Date:  2014-01       Impact factor: 9.546

8.  Predictors of dynamic hyperinflation during the 6-minute walk test in stable chronic obstructive pulmonary disease patients.

Authors:  Rui Chen; Lin Lin; Jing-Wei Tian; Bin Zeng; Lei Zhang; Xin Chen; Hai-Yan Yan
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

9.  [Main parameters of lung function in chronic obstructive pulmonary disease (COPD)].

Authors:  J M Marín Trigo
Journal:  Aten Primaria       Date:  2003       Impact factor: 1.137

10.  Randomized, double-blind, placebo-controlled superiority trial of the Yiqigubiao pill for the treatment of patients with chronic obstructive pulmonary disease at a stable stage.

Authors:  Feng-Sen Li; Yan-Li Zhang; Zheng Li; Dan Xu; Chun-Yan Liao; Huan Ma; Li Gong; Jun Su; Qi Sun; Qian Xu; Zhen Gao; Ling Wang; Jing Jing; Jing Wang; Min Jiang; Ge Tian; Bilal Hasan
Journal:  Exp Ther Med       Date:  2016-09-06       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.